The Lyssavirus glycoprotein: A key to cross-immunity

Area of Science:

• Virology
• Immunology
• Structural Biology

Background:

• Rabies is a fatal viral encephalomyelitis caused by Lyssaviruses, with rabies virus (RABV) being the most studied.
• Current efforts focus on improving post-exposure prophylaxis using monoclonal antibodies (mAbs) targeting the RABV glycoprotein (G protein).

Purpose of the Study:

• To explore the cross-neutralization capacity of existing anti-rabies mAbs.
• To discover novel B-cell epitopes on Lyssavirus glycoproteins for broader therapeutic potential.

Main Methods:

• Analysis of conserved and variable regions in available Lyssavirus glycoprotein sequences.
• Mapping sequence data onto a representative G protein structure.
• Identification of potential cross-neutralizing B-cell epitopes.

Main Results:

• Several potential cross-neutralizing B-cell epitopes (GUVTTTF, WLRTV, REECLD, EHLVVEEL) were identified.
• These epitopes complement previously characterized antigenic sites on the G protein.
• Sequence analysis revealed conserved and variable regions crucial for antibody binding.

Conclusions:

• The identified epitopes could facilitate the development of novel, cross-reactive mAbs.
• This research may lead to improved treatments not only for RABV but potentially for all Lyssavirus infections.
• Understanding Lyssavirus G protein variability is key to designing broad-spectrum antiviral therapies.